Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors
Status:
Completed
Trial end date:
2020-04-15
Target enrollment:
Participant gender:
Summary
This is an open-label Phase 1b study designed to confirm the tolerability and safety of
lenvatinib in combination with pembrolizumab in participants with selected solid tumors
(non-small cell lung cancer, predominantly clear cell renal cell carcinoma, endometrial
carcinoma, urothelial carcinoma, squamous cell carcinoma of the head and neck, or melanoma
[excluding uveal melanoma]).